The company achieved FY 2025 revenue of $85.3M, cut over $40M in annualized costs, and ended with about $550M cash. Following the strategic sale of SomaLogic to Illumina, Standard BioTools entered 2026 with a streamlined business and approximately $1 billion in NOL carryforwards, providing significant flexibility for disciplined M&A.
Cyborg Score Rationale
The company is currently unprofitable and not forecast to become profitable over the next 3 years, yet gross margins improved to 47.8% for Q4 and 49.9% for the year. Analyst consensus rating is "Reduce" with a price target of $1.35.
Top Insights
Company operationalized over $40 million in annualized cost savings while reinforcing progress toward achieving 2026 profitability targets
Net loss narrowed to $58.8M in 2025 while margins improved and cash rose following the SomaLogic transaction
Standard BioTools operates in two segments: Proteomics and Genomics
2026 revenue guidance of $80-85 million with seasonality similar to prior years
Named Competitors
Flow cytometry and mass spectrometry platforms — Leading competitor in cell analysis instrumentation
Single-cell genomics platforms — Major competitor in single-cell sequencing solutions
Spatial biology solutions — Competitor in spatial transcriptomics and imaging
Recent Developments
(February 2026) Completed sale of SomaLogic to Illumina for $350M upfront plus earnouts
(February 2026) Q4 2025 revenue beat at $23.8M vs. $18.5M estimate; EPS of $0.05 vs. ($0.03) forecast
(January 2026) Exited 2025 with approximately $550M in cash and investments post-SomaLogic deal
(February 2026) Guided 2026 revenue to $80-85M range
Open the full interactive Standard BioTools Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.